12月18日，兴齐眼药跌0.69%，成交额2.31亿元。两融数据显示，当日兴齐眼药获融资买入额2699.12万 元，融资偿还2830.95万元，融资净买入-131.84万元。截至12月18日，兴齐眼药融资融券余额合计11.87 亿元。 责任编辑：小浪快报 融券方面，兴齐眼药12月18日融券偿还1.73万股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量7.78万股，融券余额526.47万元，低于近一年40%分位水平，处于较低位。 资料显示，沈阳兴齐眼药股份有限公司位于辽宁省沈阳市沈河区青年大街125号企业广场B座30层，成 立日期1977年3月24日，上市日期2016年12月8日，公司主营业务涉及眼科药物研发、生产、销售。主营 业务收入构成为：滴眼剂82.15%，凝胶剂/眼膏剂16.70%，其他(补充)1.15%。 截至9月30日，兴齐眼药股东户数5.41万，较上期增加16.85%；人均流通股3480股，较上期减少 14.42%。2025年1月-9月，兴齐眼药实现营业收入19.04亿元，同比增长32.27%；归母净利润5.99亿元， 同比增长105.98%。 分红方面，兴齐眼药A股上市后 ...

Group 1: National Drug Procurement - The 11th batch of national drug centralized procurement includes 55 drugs, covering common medications in areas such as anti-infection, anti-allergy, anti-tumor, blood sugar, blood pressure, and blood lipid reduction [1] - The average price difference of selected products has significantly narrowed compared to previous batches, indicating a more competitive environment [1] - Measures such as excluding products with a scale below 100 million yuan from procurement and setting "anchor prices" have been implemented to maintain a reasonable selection rate and promote rational competition among companies [1] Group 2: Xingqi Eye Pharmaceutical - Xingqi Eye Pharmaceutical reported a revenue of approximately 1.904 billion yuan for the first three quarters, a year-on-year increase of 32.27% [2] - The net profit attributable to shareholders reached approximately 599 million yuan, reflecting a substantial year-on-year growth of 105.98% [2] - The increase in revenue is primarily driven by the sales growth of eye drop products, showcasing the company's strong market competitiveness in a challenging environment [2] Group 3: Novartis - Novartis reported a total revenue of 41.196 billion USD for the first three quarters, representing an 11% year-on-year growth [3] - Revenue from the Chinese market for the same period reached 3.2 billion USD, with a year-on-year growth of 5% [3] - The company has ten blockbuster products with cumulative sales exceeding 1 billion USD, indicating solid market competitiveness despite a slowdown in growth in China [3] Group 4: Qianxin Biotech and Roche - Qianxin Biotech announced a global exclusive licensing agreement with Roche for its self-developed long-acting dual antibody QX031N, receiving an upfront payment of 75 million USD [4] - The agreement includes potential milestone payments of up to 995 million USD and tiered royalties on future product sales [4] - This collaboration highlights Qianxin Biotech's R&D competitiveness and the recognition of Chinese innovative pharmaceutical companies by multinational firms, potentially attracting more capital to the Chinese innovation drug sector [4] Group 5: Haili Biotech - Haili Biotech responded to a regulatory inquiry regarding its semi-annual report, explaining the high accounts receivable due to industry pressures and efforts to maintain core customer relationships [5] - The company indicated that the increase in accounts receivable is a strategic move, but it may pose long-term risks if collections are ineffective [5] - Investors are advised to closely monitor the company's accounts receivable management and industry conditions to assess its long-term investment value [5]

Group 1: National Drug Procurement - The 11th batch of national drug centralized procurement includes 55 drugs, covering common medications in areas such as anti-infection, anti-allergy, anti-tumor, blood sugar reduction, blood pressure reduction, and blood lipid reduction [1] - The average price difference of selected products has significantly narrowed compared to previous batches, indicating a more competitive environment [1] - Measures such as excluding products with a scale below 100 million yuan, setting "anchor prices" to prevent extreme low-price impacts, and introducing a revival mechanism have maintained a relatively high selection rate, promoting rational competition and industry innovation [1] Group 2: Xingqi Eye Pharmaceutical - Xingqi Eye Pharmaceutical reported a net profit increase of 105.98% in the first three quarters, with revenue of approximately 1.904 billion yuan, a year-on-year increase of 32.27% [2] - The increase in revenue is primarily attributed to the sales growth of eye drop products, demonstrating strong market competitiveness [2] - This performance is expected to enhance investor confidence and attract more capital into the company [2] Group 3: Novartis - Novartis reported a 5% revenue growth in the Chinese market for the first three quarters, with total revenue of 4.1196 billion USD, a year-on-year increase of 11% [3] - The company has ten blockbuster products with cumulative sales exceeding 1 billion USD each, indicating solid market competitiveness [3] - However, the slowdown in revenue growth in the Chinese market is noteworthy amidst a complex global economic environment [3] Group 4: Qianxin Biotech and Roche - Qianxin Biotech has entered into a global exclusive licensing agreement with Roche for its self-developed long-acting dual antibody QX031N, receiving an upfront payment of 75 million USD and potential milestone payments up to 995 million USD [4] - QX031N targets TSLP and IL-33, showcasing the company's R&D competitiveness and recognition from multinational pharmaceutical companies [4] - This collaboration is expected to attract more capital attention to China's innovative drug sector and promote overall industry development [4] Group 5: Haili Biotech - Haili Biotech responded to regulatory inquiries regarding its semi-annual report, explaining the high accounts receivable due to industry downturn pressures and efforts to maintain core customer relationships by extending payment terms [5] - While this strategy aims to stabilize customer relations, it may increase bad debt risks if accounts receivable are not effectively collected, potentially eroding profits [5] - Investors are advised to closely monitor the company's accounts receivable management measures and changes in the industry environment to assess its long-term investment value [5]

Core Viewpoint - Xingqi Eye Pharmaceutical (300573) reported strong financial performance for Q3 2025, with significant growth in both revenue and net profit driven by increased sales of eye drop products [1] Financial Performance - Q3 2025 revenue reached 741 million yuan, representing a year-on-year increase of 35.34% [1] - Q3 2025 net profit was 264 million yuan, showing a year-on-year growth of 117.45% [1] - For the first three quarters of 2025, total revenue was 1.904 billion yuan, up 32.27% compared to the same period last year [1] - Net profit for the first three quarters of 2025 amounted to 599 million yuan, reflecting a year-on-year increase of 105.98% [1] - Basic earnings per share for the first three quarters were 2.44 yuan [1] Product Performance - The growth in revenue for the first three quarters was primarily attributed to the increase in sales revenue from eye drop products [1]

Group 1 - The core viewpoint of the news is the performance and market position of Xingqi Eye Pharmaceutical, which saw a stock price increase of 5.01% to 78.00 CNY per share, with a trading volume of 1.249 billion CNY and a turnover rate of 8.64%, resulting in a total market capitalization of 19.137 billion CNY [1] - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, specializes in the research, production, and sales of ophthalmic drugs, with its main revenue sources being eye drops (82.15%), gel/ointment (16.70%), and other supplementary products (1.15%) [1] Group 2 - From the perspective of major fund holdings, Nord Fund has a significant position in Xingqi Eye Pharmaceutical, with its Nord Quality Consumption Fund (011078) increasing its holdings by 31,400 shares in the second quarter, totaling 133,600 shares, which represents 2.75% of the fund's net value, ranking as the seventh largest holding [2] - The Nord Quality Consumption Fund, established on February 10, 2021, has a current size of 251 million CNY and has achieved a year-to-date return of 19.76%, ranking 4494 out of 8226 in its category, with a one-year return of 17.79%, ranking 4502 out of 8099 [2] - The fund manager, Xie Yi, has been in the position for 10 years and 114 days, overseeing a total fund size of 272 million CNY, with the best return during his tenure being 125.72% and the worst being -24.32% [2]

Group 1 - The core point of the news is the performance of Xingqi Eye Pharmaceutical Co., Ltd., which saw a stock price increase of 5.01% to 78.00 CNY per share, with a trading volume of 1.249 billion CNY and a turnover rate of 8.64%, resulting in a total market capitalization of 19.137 billion CNY [1] - The company, established on March 24, 1977, and listed on December 8, 2016, specializes in the research, production, and sales of ophthalmic drugs, with its main revenue sources being eye drops (82.15%), gel/ointment (16.70%), and other products (1.15%) [1] Group 2 - From the perspective of fund holdings, a fund under Zheshang Securities Asset Management has a significant position in Xingqi Eye Pharmaceutical, with the Zheshang Huijin Transformation Driver fund (001540) holding 33,300 shares, accounting for 3.18% of the fund's net value, ranking as the ninth largest holding [2] - The Zheshang Huijin Transformation Driver fund was established on July 27, 2015, with a latest scale of 54.3128 million CNY, achieving a year-to-date return of 9.92% and a one-year return of 7.91% [2]

Core Points - The stock of Xingqi Eye Pharmaceutical increased by 5.05%, reaching a price of 74.95 CNY per share, with a trading volume of 9.83 billion CNY and a turnover rate of 7.23%, resulting in a total market capitalization of 183.89 billion CNY [1] Company Overview - Xingqi Eye Pharmaceutical Co., Ltd. is located in Shenyang, Liaoning Province, and was established on March 24, 1977. The company went public on December 8, 2016. Its main business involves the research, production, and sales of ophthalmic drugs [1] - The revenue composition of the company includes eye drops at 82.15%, gel/eye ointments at 16.70%, and other supplementary products at 1.15% [1] Shareholder Information - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2,516,300 shares, which represents 1.34% of the circulating shares. The estimated floating profit today is approximately 9.0588 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion CNY. Year-to-date returns are 24.28%, ranking 1813 out of 4219 in its category, while the one-year return is 31.22%, ranking 1616 out of 3866. Since inception, the return is 135.8% [2] Fund Manager Information - The fund manager of Southern CSI 500 ETF is Luo Wenjie, who has a cumulative tenure of 12 years and 185 days. The total asset scale of the fund is 138.999 billion CNY, with the best fund return during his tenure being 145.85% and the worst being -47.6% [3] Fund Holdings - Southern Fund's Southern Big Data 300 Index A (001420) also holds shares in Xingqi Eye Pharmaceutical, with 47,800 shares held in the second quarter, accounting for 0.93% of the fund's net value, ranking as the seventh largest holding. The estimated floating profit today is about 171,900 CNY [4] - The Southern Big Data 300 Index A was established on June 24, 2015, with a latest scale of 2.17 billion CNY. Year-to-date returns are 35.06%, ranking 1020 out of 4219, while the one-year return is 51.42%, ranking 611 out of 3866. Since inception, the return is 79.19% [4] Additional Fund Manager Information - The fund manager of Southern Big Data 300 Index A is Xie Rui, who has a cumulative tenure of 3 years and 246 days. The total asset scale of the fund is 2.012 billion CNY, with the best fund return during his tenure being 19.27% and the worst being -0.23% [5]

Group 1 - The core point of the news is the significant increase in the stock price of Xingqi Eye Pharmaceutical, which rose by 5.05% to 74.95 CNY per share, with a trading volume of 983 million CNY and a turnover rate of 7.24%, leading to a total market capitalization of 18.389 billion CNY [1] - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, specializes in the research, production, and sales of ophthalmic drugs, with its main business revenue composition being 82.15% from eye drops, 16.70% from gel/eye ointments, and 1.15% from other supplementary products [1] Group 2 - From the perspective of fund holdings, Guolian An Fund has a significant position in Xingqi Eye Pharmaceutical, with its Guolian An New Selected Mixed A Fund (000417) increasing its holdings by 1,800 shares in the second quarter, totaling 16,800 shares, which represents 2.58% of the fund's net value, making it the sixth-largest holding [2] - The Guolian An New Selected Mixed A Fund, established on March 4, 2014, has a latest scale of 33.7121 million CNY, with a year-to-date return of 8.1% and a one-year return of 9.58%, ranking 5,947 out of 8,095 in its category [2] - The fund manager, Zhang Zhenyuan, has been in the position for 11 years and 323 days, managing total assets of 40.811 billion CNY, with the best fund return during his tenure being 387.76% and the worst being -35.8% [2]

Core Insights - On October 15, Xingqi Eye Pharmaceutical Co., Ltd. saw a stock price increase of 5.1%, reaching 69.02 CNY per share, with a trading volume of 390 million CNY and a turnover rate of 3.08%, resulting in a total market capitalization of 16.934 billion CNY [1] Company Overview - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, is located in Shenyang, Liaoning Province. The company specializes in the research, production, and sales of ophthalmic drugs [1] - The revenue composition of the company includes eye drops at 82.15%, gel/ointment at 16.70%, and other supplementary products at 1.15% [1] Shareholder Insights - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2.5163 million shares, which represents 1.34% of the circulating shares. The estimated floating profit today is approximately 8.4297 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a current scale of 113.438 billion CNY. Year-to-date returns stand at 27.41%, ranking 1733 out of 4220 in its category, while the one-year return is 30.04%, ranking 1557 out of 3857. Since inception, the fund has achieved a return of 141.75% [2] Fund Performance - The fund manager of Southern CSI 500 ETF is Luo Wenjie, who has a tenure of 12 years and 180 days. The total asset scale under his management is 138.999 billion CNY, with the best fund return during his tenure being 152.82% and the worst being -47.6% [3] - Another fund, Southern Big Data 300 Index A (001420), also holds a significant position in Xingqi Eye Pharmaceutical, with 47,800 shares, accounting for 0.93% of the fund's net value. The estimated floating profit today is around 160,000 CNY [4] - The Southern Big Data 300 Index A was established on June 24, 2015, with a current scale of 2.17 billion CNY. Year-to-date returns are 37.99%, ranking 973 out of 4220, while the one-year return is 51.94%, ranking 473 out of 3857. Since inception, the fund has achieved a return of 83.07% [4] Additional Fund Management Insights - The fund manager of Southern Big Data 300 Index A is Xie Rui, who has a tenure of 3 years and 241 days. The total asset scale under his management is 2.012 billion CNY, with the best fund return during his tenure being 24.17% and the worst being -0.02% [5]

Group 1 - The core point of the news is the significant increase in the stock price of Xingqi Eye Pharmaceutical, which rose by 5.1% to 69.02 CNY per share, with a trading volume of 399 million CNY and a turnover rate of 3.15%, leading to a total market capitalization of 16.934 billion CNY [1] Group 2 - Xingqi Eye Pharmaceutical, established on March 24, 1977, and listed on December 8, 2016, is located in Shenyang, Liaoning Province. The company specializes in the research, production, and sales of ophthalmic drugs [1] - The main business revenue composition of Xingqi Eye Pharmaceutical includes eye drops at 82.15%, gel/eye ointments at 16.70%, and other supplementary products at 1.15% [1] Group 3 - From the perspective of fund holdings, one fund under Zheshang Securities Asset Management has a significant position in Xingqi Eye Pharmaceutical. The Zheshang Huijin Transformation Driver fund (001540) held 33,300 shares in the second quarter, accounting for 3.18% of the fund's net value, ranking as the ninth largest holding [2] - The Zheshang Huijin Transformation Driver fund, established on July 27, 2015, has a latest scale of 54.3128 million CNY and has achieved a year-to-date return of 11.05%, ranking 5540 out of 8161 in its category [2] - The fund manager, Chen Gujun, has been in position for 5 years and 270 days, with a total asset scale of 204 million CNY. The best fund return during his tenure is 39.87%, while the worst is -7.57% [2]